Navigation Links
ASCO releases studies from upcoming annual meeting
Date:5/17/2012

ALEXANDRIA, Va. The American Society of Clinical Oncology (ASCO) today highlighted five studies in a press briefing from among more than 4,500 abstracts publicly posted online at abstract.asco.org in advance of ASCO's 47th Annual Meeting.

Plenary, late-breaking and other major studies will be released in on-site press conferences at the Annual Meeting to be held June 1-5, 2012, at McCormick Place in Chicago, Ill. The meeting, which will feature the theme Collaborating to Conquer Cancer, is expected to draw approximately 30,000 cancer specialists from around the world.

"Nearly 50 years into the era of modern oncology, we can clearly see the fruits of our research investments," said Michael Link, MD, President of ASCO. "Findings to be presented at ASCO's Annual Meeting are part of the latest chapter in the history of progress against cancer. Today's studies demonstrate improvements in precision medicine that identify and exploit cancer's genetic weak spots to halt tumor growth and in some cases eradicate disease. Other studies give us valuable new tools and information to lessen the short- and long-term side effects of cancer treatment for our patients."

Studies highlighted in today's press briefing include:

  • In early study, crizotinib induces strong, long-lasting responses in aggressive pediatric cancers: Phase I study reports that crizotinib (Xalkori) an oral drug that targets genetic abnormalities in the ALK gene stalled tumor growth and, in some cases, eliminated all signs of cancer in select children with neuroblastoma, anaplastic large cell lymphoma or inflammatory myofibroblastic tumors, cancers commonly driven by ALK gene abnormalities.

  • Combination of two molecularly targeted oral drugs show promise for advanced melanoma with BRAF mutations: Results from an early-phase trial show that combination therapy with two investigational targeted drugs the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib causes tumor regression and with a lower level of skin side effects than published studies of the current standard single-agent BRAF-targeted therapy, vemurafenib (Zelboraf), have shown.

  • Anti-psychotic medicine effective in treating severe chemotherapy-related nausea: A Phase III trial shows olanzapine (Zyprexa), an anti-psychotic medication, is superior to current standard treatment for breakthrough chemotherapy-induced nausea and vomiting. These results address an important unmet need for patients who experience such side effects, despite routine preventive treatment.

  • Adding abiraterone to standard hormone therapy eliminates cancer in some men with earlier-stage, aggressive prostate cancer: A randomized Phase II study shows that six months of neo-adjuvant (pre-surgical) treatment with the targeted drug abiraterone (Zytiga) and hormonal therapy eliminated or nearly eliminated cancer in one-third of men with localized high-risk prostate cancer (which has spread throughout the prostate and is likely to spread further). Abiraterone is currently approved for men with advanced prostate cancer, following chemotherapy.

  • Survey highlights need for greater physician education, communication about late effects of common chemotherapy drugs: A large survey finds that many primary care providers and some oncologists are not fully aware of major long-term side effects of four chemotherapy drugs that are widely used to treat breast and colorectal cancers, two of the most common forms of cancer.


'/>"/>

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology
Source:Eurekalert

0

GOOD

Related medicine news :

1. Markle releases new resources for health information sharing implementation
2. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
3. American College of Physicians releases new colorectal cancer screening guidance statement
4. Presidents Bioethics Commission releases report on human subjects protection
5. Society for Integrative Oncology releases findings presented at annual meeting
6. Health Information Technology and Patient Safety - IOM report releases Nov. 10
7. Federal government releases environmental, health, and safety research strategy for nanotechnology
8. NNI releases 4 workshop reports from the nanoEHS Series
9. ASCO releases studies from upcoming annual meeting
10. AMP releases statement on diagnostics in drug labels
11. IADR/AADR Journal of Dental Research releases studies on oral health inequalities in older people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... ... at his Inauguration that WesternU will move forward in bold new directions while ... WesternU combined Wilson’s Inauguration ceremony with Convocation, the traditional opening of the academic ...
(Date:8/15/2017)... ... August 15, 2017 , ... Horizon Goodwill is honored to ... are overwhelmed with gratitude for the very generous donation from BB&T. Our mission ... both get a job and keep it. This donation will go a long ...
(Date:8/15/2017)... ... August 15, 2017 , ... IsoComforter, Inc., one of the ... innovative new 10x10 bladder pad ( isocomforter.com/product/10x10-sterile-pad/ ). The newly designed bladder pad ... enables the patient to enjoy the benefits of cold therapy while resting, sitting, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Harris Communications, Inc. is bringing its ... Twin Cities Living Well with Hearing Loss Conference, 9:30-2 p.m. Saturday, Nov. 18 at ... for Harris Communications at tables 8 and 9. , During the conference, attendees can ...
(Date:8/15/2017)... Glan Allen,VA (PRWEB) , ... August 15, 2017 ... ... of CoolSculpting to their leading selection of services. FDA-cleared CoolSculpting is the world’s ... and counting. Without surgery or downtime, CoolSculpting can reduce fat cells in almost ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
(Date:7/25/2017)... -- Debbie,s Dream Foundation: Curing Stomach Cancer (DDF) is excited to host its 3 ... Bonaventure Resort & Spa in Weston, Florida beginning at ... Luncheon Committee Co-chair ... Luncheon Committee Co-chair Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, DDF Board Member John ...
Breaking Medicine Technology: